Tilray Brands (TLRY) Convertible Debt (2018 - 2026)
Tilray Brands (TLRY) posted Convertible Debt of $88.3 million for Q1 2026, up 2.33% on a QoQ basis from $86.3 million in Q4 2025, and down 15.18% year-over-year from $104.1 million in Q1 2025.
Tilray Brands (TLRY) Convertible Debt (2018 - 2026) Analysis & Trends
Tilray Brands' Convertible Debt history runs 9 years deep, the most recent figure standing at $88.3 million for Q1 2026.
- Quarterly Convertible Debt fell 15.18% year-over-year to $88.3 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $88.3 million (down 15.18% YoY) and the FY2025 annual result came in at $86.4 million, down 17.69% from the prior year.
- Convertible Debt was $88.3 million for Q1 2026 at Tilray Brands, up from $86.3 million in the prior quarter.
- Across five years, Convertible Debt topped out at $501.1 million in Q1 2022 and bottomed at $86.3 million in Q4 2025.
- A 5-year average of $188.9 million and a median of $123.7 million in 2023 frame the typical range for Convertible Debt.
- Annual changes were most pronounced in 2023 — Convertible Debt plunged 72.8% — and 2024, when it advanced 9.75%.
- Tilray Brands' Convertible Debt stood at $223.3 million in 2022, then sank by 44.61% to $123.7 million in 2023, then slipped by 0.77% to $122.7 million in 2024, then decreased by 29.72% to $86.3 million in 2025, then advanced by 2.33% to $88.3 million in 2026.
- Business Quant data shows TLRY's Convertible Debt at $88.3 million in Q1 2026, $86.3 million in Q4 2025, and $100.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 88.27 Mn |
| Nov 30, 2025 | 86.26 Mn |
| Aug 31, 2025 | 100.00 Mn |
| May 31, 2025 | 86.43 Mn |
| Feb 28, 2025 | 104.07 Mn |
| Nov 30, 2024 | 122.74 Mn |
| Aug 31, 2024 | 132.65 Mn |
| May 31, 2024 | 105.00 Mn |
| Feb 29, 2024 | 126.59 Mn |
| Nov 30, 2023 | 123.69 Mn |
| Aug 31, 2023 | 120.86 Mn |
| May 31, 2023 | 221.04 Mn |
| Feb 28, 2023 | 223.09 Mn |
| Nov 30, 2022 | 223.30 Mn |
| Aug 31, 2022 | 444.28 Mn |
| May 31, 2022 | 401.95 Mn |
| Feb 28, 2022 | 501.08 Mn |
| Nov 30, 2021 | 554.85 Mn |
| Aug 31, 2021 | 611.65 Mn |
| May 31, 2021 | 667.62 Mn |